Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | MicrobiomeTrials
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2027-07
Enrollment target: 22 participants
Locations
Icahn School of Medicine at Mount Sinai, New York, New York, United States